Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 8.60
- Piotroski Score 4.00
- Grade Hold
- Symbol (STAA)
- Company STAAR Surgical Company
- Price $26.22
- Changes Percentage (-0.38%)
- Change -$0.1
- Day Low $25.93
- Day High $26.34
- Year High $52.68
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $48.00
- High Stock Price Target $85.00
- Low Stock Price Target $45.03
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.31
- Trailing P/E Ratio 124.71
- Forward P/E Ratio 124.71
- P/E Growth 124.71
- Net Income $21.35 M
Income Statement
Quarterly
Annual
Latest News of STAA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Staar Surgical Co (STAA) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amidst Challenges
Thomas Frinzi, CEO of STAAR Surgical, remains optimistic about the company's growth potential despite macroeconomic uncertainties. The company has a strong track record of outperforming the market....
By Yahoo! Finance | 2 weeks ago -
Marc Staal, Alex Goligoski announce retirements after 17 NHL seasons apiece
After 17 seasons in the NHL, defenseman Marc Staal has retired and joined the New York Rangers as a player development assistant. Staal played 892 games with the Rangers and recorded 234 career points...
By USA Today | 2 months ago -
Are Investors Undervaluing STAAR Surgical Company (NASDAQ:STAA) By 44%?
STAAR Surgical's intrinsic value is estimated at US$3.3 billion, indicating a 44% undervaluation compared to its current share price. Utilizing the Discounted Cash Flow model, this analysis offers ins...
By Yahoo! Finance | 3 months ago
